Dr. Reddy’s continues to expand its portfolio

Dr. Reddy’s proudly announces the launch of Cabazitaxel for Injection, 60 mg/1.5 mL (40 mg/mL) per Single-dose Syringe. Cabazitaxel is a therapy option for mCRPC patients and the therapeutic equivalent generic version of JEVTANA® (cabazitaxel) Injection. “We are excited to expand our injectable portfolio and provide affordable medicines across Canada” says Vinod Ramachandran, Vice President and General Manager, Canada Operations, Dr. Reddy’s Laboratories.  JEVTANA® is a trademark of the Sanofi-aventis. 

Dr. Reddy’s Laboratories Canada, Inc.
5580 Explorer Drive, Suite 204, Mississauga, ON L4W 4Y1
www.drreddys.com/canada

This post is part of CAPhO’s Email Distribution Service on behalf of Dr. Reddy’s and is not an endorsement or recommendation of the product or message content.